C. Brumme

J. Joy, G. Dore, A. Poon, 2019, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

T-cell responses to sequentially emerging viral escape mutants shape long-term HIV-1 population dynamics

S. Oka, Z. Brumme, C. Brumme, 2020, PLoS pathogens.

Proviral Turnover During Untreated HIV Infection Is Dynamic and Variable Between Hosts, Impacting Reservoir Composition on ART

Richard H. Liang, J. Joy, E. Hunter, 2021, Frontiers in Microbiology.

Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5

Jaclyn K. Mann, T. Ndung’u, D. Bangsberg, 2020, PLoS pathogens.

Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes

Rosemary M. McCloskey, Jaclyn K. Mann, B. Walker, 2013, Retrovirology.

Title Ability of HIV-1 Nef to downregulate CD 4 and HLA class I differs among viral subtypes Permalink

Rosemary M. McCloskey, Jaclyn K. Mann, B. Walker, 2013 .

Characteristics and Outcomes of Initial Virologic Suppressors during Analytic Treatment Interruption in a Therapeutic HIV-1 gag Vaccine Trial

M. Carrington, B. Walker, R. Schooley, 2012, PloS one.

A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.

P. Harrigan, B. Yip, J. Montaner, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphocyte Recognition

Todd M. Allen, F. Pereyra, T. Miura, 2009, Journal of Virology.

Genetic Characterization of Human Immunodeficiency Virus Type 1 in Elite Controllers: Lack of Gross Genetic Defects or Common Amino Acid Changes

Todd M. Allen, D. Heckerman, F. Pereyra, 2008, Journal of Virology.

Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals

S. Oka, Z. Brumme, C. Brumme, 2015, Retrovirology.

Increasingly successful highly active antiretroviral therapy delays the emergence of new HLA class I-associated escape mutations in HIV-1.

P. Harrigan, B. Wynhoven, D. Knapp, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Longitudinal within-host evolution of HIV Nef-mediated CD4, HLA and SERINC5 downregulation activity: a case study

J. Joy, Z. Brumme, C. Brumme, 2020, Retrovirology.

Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use

Evan Wood, P. Harrigan, B. Yip, 2005, AIDS.

Intra-host evolutionary dynamics of the hepatitis C virus among people who inject drugs

J. Joy, C. Brumme, W. Dong, 2021, Scientific Reports.

Rates and Correlates of Short Term Virologic Response among Treatment-Naïve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study

Z. Brumme, C. Brumme, B. T. Tadesse, 2019, Pathogens.

Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping

Emma R Lee, Mark Howison, Shuntai Zhou, 2020, Viruses.

Automating HIV Drug Resistance Genotyping with RECall, a Freely Accessible Sequence Analysis Tool

Tommy F. Liu, R. Shafer, A. Chu, 2012, Journal of Clinical Microbiology.

Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults

J. Montaner, G. Umviligihozo, M. Niikura, 2021, medRxiv.

Transmission of Drug-Resistant HIV-1 from an Infected Individual to a Caregiver

P. Harrigan, J. Montaner, B. Wynhoven, 2007, Antiviral therapy.

Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda.

Jeffrey N. Martin, P. Harrigan, D. Knapp, 2014, AIDS research and human retroviruses.

Are We Ready for NGS HIV Drug Resistance Testing? The Second “Winnipeg Consensus” Symposium

R. Paredes, P. Harrigan, N. Parkin, 2020, Viruses.

Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy.

P. Harrigan, R. Hogg, J. Montaner, 2007, The Journal of infectious diseases.

Understanding patterns of HIV multi-drug resistance through models of temporal and spatial drug heterogeneity

P. Pennings, C. Brumme, K. Harper, 2019, eLife.

Structure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infection

G. Gao, J. Carlson, Yi Shi, 2013, Scientific Reports.

Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals.

P. Harrigan, R. Hogg, J. Montaner, 2005, The Journal of infectious diseases.

HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach.

P. Harrigan, J. Montaner, B. Wynhoven, 2005, The Journal of infectious diseases.

Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine

J. Montaner, M. DeMarco, M. Niikura, 2023, Open forum infectious diseases.

Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine

J. Montaner, M. DeMarco, M. Niikura, 2023, Open forum infectious diseases.

Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine

J. Montaner, M. DeMarco, G. Umviligihozo, 2021, medRxiv.

Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose

J. Montaner, M. DeMarco, G. Umviligihozo, 2022, medRxiv.

Detection of HIV transmission hotspots in British Columbia, Canada: A novel framework for the prioritization and allocation of treatment and prevention resources

J. Montaner, J. Joy, P. Sereda, 2019, EBioMedicine.

SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy

Richard H. Liang, M. Niikura, Z. Brumme, 2023, AIDS.

Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification

P. Harrigan, J. Montaner, Lu Wang, 2017, PloS one.

Replication Fitness of Multiple Nonnucleoside Reverse Transcriptase-Resistant HIV-1 Variants in the Presence of Etravirine Measured by 454 Deep Sequencing

P. Harrigan, A. Poon, K. Huber, 2013, Journal of Virology.

Trends in Plasma HIV-RNA Suppression and Antiretroviral Resistance in British Columbia, 1997–2010

P. Harrigan, R. Hogg, J. Montaner, 2014, Journal of acquired immune deficiency syndromes.

Technical and Regulatory Shortcomings of the TaqMan Version 1 HIV Viral Load Assay

B. Yip, J. Montaner, B. Wynhoven, 2012, PloS one.

Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches

Jeffrey N. Martin, P. Harrigan, M. Siedner, 2017, AIDS.

Longitudinal trends of HIV drug resistance in a large Canadian cohort, 1996-2016.

P. Harrigan, J. Shoveller, C. Brumme, 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

HIV reservoirs are dominated by genetically younger and clonally enriched proviruses

J. Joy, R. B. Jones, Z. Brumme, 2023, bioRxiv.

Curing HIV will require eliminating the reservoir of integrated, replication-competent proviruses

Richard H. Liang, B. Walker, A. Trocha, 2021 .

Theoretical and experimental assessment of degenerate primer tagging in ultra-deep applications of next-generation sequencing

Jeffrey B. Joy, Richard H. Liang, Rosemary M. McCloskey, 2014, Nucleic acids research.

Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.

P. Harrigan, R. Hogg, J. Montaner, 2005, Antiviral therapy.

"Test-and-treat" strategy for control of HIV and AIDS can lead to a decrease, not an increase, of multidrug-resistant viruses.

P. Harrigan, J. Montaner, C. Brumme, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy

J. Montaner, M. DeMarco, G. Umviligihozo, 2022, AIDS.